Anthony Laurence Zietman

Anthony Laurence Zietman's AcademicInfluence.com Rankings

Philosophy

#7214

World Rank

#10395

Historical Rank

Logic

#4279

World Rank

#5550

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Anthony Laurence Zietman's Degrees

Doctorate Medicine Harvard University

Why Is Anthony Laurence Zietman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Anthony Laurence Zietman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. (2005) (1239)
Early detection of prostate cancer: AUA Guideline. (2013) (1061)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. (2001) (703)
Changes in body composition during androgen deprivation therapy for prostate cancer. (2002) (649)
Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) (612)
Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. (2010) (570)
Prostate specific antigen best practice statement: 2009 update. (2009) (556)
Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. (1999) (463)
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. (2007) (461)
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer (2017) (449)
Outcomes of localized prostate cancer following conservative management. (2009) (434)
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. (2012) (416)
Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. (1995) (406)
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. (2012) (379)
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. (2012) (375)
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. (2010) (324)
Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. (2002) (314)
Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. (2014) (312)
Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group (2012) (312)
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. (2003) (270)
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. (2016) (266)
Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. (1994) (241)
Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. (2002) (229)
Bladder preservation by combined modality therapy for invasive bladder cancer. (1997) (223)
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. (2007) (222)
Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. (2003) (222)
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. (2013) (206)
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. (2003) (201)
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. (2017) (201)
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. (2009) (189)
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. (2003) (188)
Malignant Lymphoma of the Testis, Epididymis, and Spermatic Cord: A Clinicopathologic Study of 69 Cases with Immunophenotypic Analysis (1994) (187)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. (2004) (185)
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. (2004) (183)
Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. (1997) (182)
Management of Complications of Prostate Cancer Treatment (2008) (169)
Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. (1994) (161)
The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. (1995) (160)
The management of spermatic cord sarcoma (1996) (151)
Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. (1997) (144)
Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer (2008) (143)
Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. (2000) (139)
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. (2003) (136)
Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. (2001) (131)
Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. (2005) (129)
Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. (1994) (124)
Comparison of biochemical failure definitions for permanent prostate brachytherapy. (2005) (123)
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. (2012) (122)
Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. (1996) (117)
Radiotherapy for bladder cancer. (2007) (113)
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D (2014) (113)
Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. (2002) (112)
Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. (2015) (112)
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. (2012) (112)
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. (2020) (109)
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. (2013) (109)
Comparison of Population-Based Observational Studies With Randomized Trials in Oncology. (2019) (109)
Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. (2002) (105)
Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications (1993) (103)
Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. (2004) (103)
Promise and pitfalls of heavy-particle therapy. (2014) (102)
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. (2010) (101)
Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. (2004) (97)
Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. (2001) (96)
Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. (1996) (95)
Localized carcinoma of the prostate (Stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy (1993) (94)
Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. (2001) (91)
Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. (1993) (87)
Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. (2010) (86)
Adenovirus‐mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo (2005) (86)
Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer (2013) (85)
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. (2009) (84)
The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. (1997) (82)
A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. (1998) (82)
Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. (2017) (80)
Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. (2002) (77)
Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. (2011) (77)
Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. (2007) (76)
An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. (1999) (73)
Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. (2005) (70)
Quantitative studies on the transplantability of murine and human tumors into the brain and subcutaneous tissues of NCr/Sed nude mice. (1988) (67)
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. (2015) (67)
Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features (2018) (66)
Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. (2014) (65)
Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. (1990) (64)
Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. (1997) (64)
Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. (2011) (62)
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. (2019) (62)
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. (2020) (62)
Trimodality bladder preservation therapy for muscle-invasive bladder cancer. (2013) (59)
Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. (2007) (59)
Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. (1993) (59)
Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. (2017) (58)
Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone (2006) (57)
Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life (2016) (56)
Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. (2001) (54)
The effect of pelvic radiation therapy on serum levels of prostate specific antigen. (1994) (54)
Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses. (1994) (52)
Survivin is a potential mediator of prostate cancer metastasis. (2010) (51)
Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. (1997) (51)
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. (2012) (50)
The Titanic and the Iceberg: prostate proton therapy and health care economics. (2007) (49)
Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. (1989) (49)
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. (2020) (46)
Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. (1994) (45)
Bladder preservation: optimizing radiotherapy and integrated treatment strategies (2008) (45)
The combination of cis-platin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. (1993) (44)
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? (2003) (44)
PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure. (2005) (44)
Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. (2008) (43)
Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. (1996) (43)
Radiation Therapy Research: A Global Analysis 2001-2015. (2018) (42)
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist (2014) (42)
Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up. (2001) (42)
Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. (2012) (42)
Loss of heterozygosity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease. (1998) (41)
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee (2016) (40)
Technology evolution: is it survival of the fittest? (2010) (40)
Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. (2013) (40)
Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. (2010) (39)
Residual immunity of athymic NCr/sed nude mice and the xenotransplantation of human tumors (1990) (39)
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. (2016) (39)
Life, Liberty, and the Pursuit of Protons: An Evidence-Based Review of the Role of Particle Therapy in the Treatment of Prostate Cancer (2009) (39)
Proton beam therapy and localised prostate cancer: current status and controversies (2013) (39)
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. (2014) (39)
Developing a national radiation oncology registry: From acorns to oaks. (2012) (38)
10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. (2004) (38)
Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. (2011) (37)
A randomized trial comparing conventional dose (70.2GyE) and high-dose (79.2GyE) conformal radiation in early stage adenocarcinoma of the prostate: Results of an interim analysis of PROG 95–09 (2004) (37)
Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. (2016) (36)
Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. (2017) (36)
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. (2017) (34)
Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. (2012) (34)
Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer (2018) (34)
Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. (2013) (34)
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. (2013) (34)
Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. (2012) (33)
Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. (2000) (32)
Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy (2000) (32)
Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder (2004) (32)
Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention (2003) (31)
Why does androgen deprivation enhance the results of radiation therapy? (2008) (31)
Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. (2013) (30)
Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. (2012) (30)
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. (2006) (30)
Maximizing dosimetric benefits of IMRT in the treatment of localized prostate cancer through multicriteria optimization planning. (2013) (30)
Proton beam therapy and accountable care: the challenges ahead. (2013) (30)
The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. (2001) (30)
Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. (2018) (29)
Clinical Embryology: A Color Atlas and Text (1998) (29)
The response of two human tumor xenografts to fractionated irradiation. The derivation of alpha/beta ratios from growth delay, tumor control, and in vitro cell survival assays. (1990) (28)
Long‐term quality of life after definitive treatment for prostate cancer: patient‐reported outcomes in the second posttreatment decade (2017) (28)
Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. (2014) (27)
The Management and Outcome of Stage IA sub E Nonhodgkin's Lymphoma of the Testis (1996) (27)
Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. (2016) (27)
What is the optimal management of high risk, clinically localized prostate cancer? (2010) (26)
Attitudes toward blinding of peer review and perceptions of efficacy within a small biomedical specialty. (2014) (26)
The Radiation Oncology Job Market: The Economics and Policy of Workforce Regulation. (2016) (26)
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. (2012) (26)
United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. (2002) (26)
Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA (2016) (26)
Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. (1994) (25)
Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. (2016) (25)
Falsification, fabrication, and plagiarism: the unholy trinity of scientific writing. (2013) (24)
Bringing radiation therapy to underserved nations: an increasingly global responsibility in an ever-shrinking world. (2014) (24)
Proton radiation for localized prostate cancer (2009) (24)
Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. (2003) (24)
Clinical controversies: proton therapy for prostate cancer. (2013) (24)
The future of radiation oncology: the evolution, diversification, and survival of the specialty. (2008) (23)
Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations (2017) (23)
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (2006) (23)
The American Board of Radiology Holman Research Pathway: 10-year retrospective review of the program and participant performance. (2013) (23)
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. (2017) (22)
Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? (2008) (22)
Evaluation of Adherence to Quality Measures for Prostate Cancer Radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey. (2013) (22)
The results of concurrent chemo‐radiotherapy for recurrence after treatment with bacillus Calmette‐Guérin for non‐muscle‐invasive bladder cancer: is immediate cystectomy always necessary? (2009) (21)
Organ-Sparing Treatment of Advanced Bladder Cancer (2007) (21)
The ‘CaP Calculator’: an online decision support tool for clinically localized prostate cancer (2010) (21)
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? (2011) (20)
Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. (2006) (20)
Radiation-based approaches to the management of T3 prostate cancer. (1997) (20)
An Update of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer (1998) (20)
Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice. (1988) (20)
Proton beam and prostate cancer: An evolving debate. (2013) (20)
Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. (2008) (20)
Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient. (1996) (20)
Bladder-sparing approaches to invasive disease (2006) (20)
Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. (2017) (19)
Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. (1997) (19)
New life after prostate brachytherapy? Considering the fertile female partner of the brachytherapy patient (2005) (18)
Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. (2002) (18)
A comparative study on the xenotransplantability of human solid tumors into mice with different genetic immune deficiencies (1991) (18)
Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. (2007) (17)
Making Radiation Therapy for Prostate Cancer More Economical and More Convenient. (2016) (17)
Too Big to Fail? The Current Status of Proton Therapy in the USA. (2017) (17)
High-Dose External Beam Radiation for Localized Prostate Cancer: Current Status and Future Challenges (2007) (17)
The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. (1999) (17)
Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. (1996) (17)
Quality of life after radical treatment for invasive bladder cancer. (2005) (17)
Receiving the Torch (2012) (16)
Using patient‐reported outcomes to assess and improve prostate cancer brachytherapy (2014) (16)
Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer (2013) (16)
Enhancing Career Paths for Tomorrow's Radiation Oncologists. (2019) (16)
Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. (2008) (16)
Organ-sparing treatment for bladder cancer: time to beat the drum. (1994) (16)
A clinical approach to technology assessment: how do we and how should we choose the right treatment? (2012) (16)
External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis (2008) (16)
Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. (2007) (15)
Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years (2019) (15)
Radiation therapy or prostatectomy: an old conflict revisited in the PSA era. A radiation oncologist's viewpoint. (1998) (15)
Radiation therapy in the management of early stage Hodgkin's disease presenting in later life (1991) (15)
Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial (2019) (15)
Models of care and NCCN guideline adherence in very-low-risk prostate cancer. (2013) (14)
Localized prostate cancer: brachytherapy (2002) (14)
Quantitative comparison between the transplantability of human and murine tumors into the brain of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. (1993) (14)
Prostate specific antigen best practice statement: 2009 update. (2013) (13)
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. (2004) (13)
Fate of manuscripts rejected from the Red Journal. (2015) (13)
Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams (2017) (13)
Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. (2009) (13)
Introducing prospective manuscript review to address publication bias. (2014) (13)
Prostatic Duct Adenocarcinoma: Clinical Characteristics, Treatment Options, and Outcomes – a Rare Cancer Network Study (2010) (13)
Particle Therapy at the "Tipping Point": An Introduction to the Red Journal's Special Edition. (2016) (12)
A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. (2016) (12)
NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. (2016) (12)
The Ethics of Scientific Publishing: Black, White, and "Fifty Shades of Gray". (2017) (12)
Taking "the Game" Out of The Match: A Simple Proposal. (2015) (12)
The management and outcome of stage IAE nonHodgkin's lymphoma of the testis. (1996) (11)
Letters Regarding the TARGIT-A Trial: The Editor's Introduction. (2015) (11)
The biochemical and clinical significance of the post-treatment PSA bounce for prostate cancer patients treated with external beam radiation therapy alone: A multi-institutional pooled analysis (2004) (11)
The case for neoadjuvant androgen suppression before radiation therapy. (2000) (11)
Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. (2016) (11)
Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. (2021) (11)
42 A phase trial of transurethral surgery plus cisplatin and radiation therapy followed by either selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis (1997) (10)
The red journal's top 10 most downloaded articles of 2011. (2012) (10)
The impact of MRE11 in nuclear to cytoplasmic ratio on outcomes in muscle invasive bladder cancer an analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2017) (10)
Introducing: The Red Journal Gray Zone. (2017) (10)
Outcomes of Selective Bladder Preservation in the Elderly Treated With Conservative Surgery and Chemoradiation (2013) (10)
Dose escalation in localized prostate cancer: make no assumptions. (2002) (10)
Too much impact? Scientific journals and the "impact factor". (2014) (9)
Proton Beam Therapy in Localized Prostate Cancer (2000) (9)
Comparative effectiveness research in localized prostate cancer treatment. (2013) (9)
Radiation oncology authors and reviewers prefer double-blind peer review (2018) (9)
An organ-preserving approach to muscle-invading transitional cell cancer of the bladder. (2001) (9)
97 A randomized trial comparing local tumor control following irradiation alone versus combined androgen withdrawal and irradiation in an androgen sensitive prostate cancer xenograft (1995) (9)
When should radiation therapy follow radical prostatectomy in the management of prostatic cancer? (1994) (8)
The Red Journal's most downloaded articles of 2012. (2013) (8)
Primary radiotherapy vs conservative management for localized prostate cancer—a population-based study (2015) (8)
Muscle-Invasive Bladder Cancer (2003) (8)
Improving Diversity and Inclusion in the Post–Coronavirus Disease 2019 Era Through a Radiation Oncology Intensive Shadowing Experience (RISE) (2020) (8)
A Prospective Phase I/II Study using Proton Beam Radiation to Deliver 82GyE to Men with Localized Prostate Cancer: Preliminary Results of ACR 0312 (2008) (8)
Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer. (1997) (8)
Old drugs, new purpose--bladder cancer turning a corner. (2012) (8)
Impact of interfractional motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer (2018) (8)
Top ten clinical research downloads of 2011. (2012) (8)
Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. (2013) (8)
Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2012) (8)
Active surveillance for prostate cancer: the role of the pathologist. (2015) (8)
Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy (2010) (7)
The Red Journal's Outstanding Reviewer Awards for 2012 (2013) (7)
Dose-Escalated Radiotherapy for Prostate Cancer: Is the Sky the Limit? (2015) (7)
Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields. (2012) (7)
Case records of the Massachusetts General Medicine. Weekly clinicopathological exercises. Case 9-2003. An 18-year-old man with back and leg pain and a nondiagnostic biopsy specimen. (2003) (7)
Fractionation sensitivity and immunological status in radiation treated murine sarcomas. (1990) (7)
Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long‐term Results of a Single‐institution Experience (2017) (6)
Opportunities with combined modality therapy for selective organ preservation in muscle‐invasive bladder cancer (1996) (6)
Results of a randomized trial of total radiation for stage T3-T4 prostate cancer boosting with photons (to 67.2 cge) or with conformal protons (to 75.6 CGE) (1994) (6)
Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer. (2022) (6)
Progress in the management of T3-4 adenocarcinoma of the prostate. (1997) (6)
A fork in the road: choosing the path of relevance. (2015) (6)
Prostate cancer. Who is best benefited by external beam radiation therapy? (1996) (6)
The four Rs of the Red Journal: a progress report from the new editorial team. (2013) (6)
Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early‐stage prostate cancer (2017) (6)
International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties. (2016) (6)
Adjuvant radiation therapy for pathologic T3 prostate cancer (1993) (6)
308: An Update of Selective Bladder Preservation Using Combined Modality Treatment in Invasive Bladder Cancer: Long Term Outcome Reveals a Low Risk of Invasive Recurrence and a High Probability of Bladder Preservation (2004) (6)
The life shortening effects of treatment with doxorubicin and/or local irradiation on a cohort of young C3Hf/Sed mice. (1991) (5)
Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2012) (5)
Long-term quality of life after conventional-dose versus high-dose radiation for prostate cancer: Results from a randomized trial (PROG 95–09) (2008) (5)
The durability of PSA failure-free survival from 5 years to 13 years following radiotherapy in patients with localized prostate cancer (2000) (5)
Clinical Trial Registration: A Mandatory Requirement for Publication in the Red Journal (2015) (5)
The value of external beam radiation in node positive prostate cancer (2001) (5)
Painting Dose: The ART of Radiation. (2016) (5)
The radiation oncology milestone project. (2014) (5)
1141 Selective bladder preservation by combined modality therapy for invasive bladder cancer (1995) (5)
RETRACTED: High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis Int J Radiat Oncol Biol Phys 2012;83:e619-e625. (2013) (5)
The Red Journal's top downloads of 2013. (2014) (5)
Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy (2008) (5)
Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay (2019) (5)
The Impact of MRE11 in Nuclear to Cytoplasmic Ratio on Outcomes in Muscle Invasive Bladder Cancer: an Analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2017) (5)
Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial. (2021) (5)
ASTRO Journals’ Data Sharing Policy and Recommended Best Practices (2019) (5)
ACTIVE SURVEILLANCE: A SAFE, LOW‐COST PROGNOSTIC TEST FOR PROSTATE CANCER (2008) (5)
Can proton therapy be considered a standard of care in oncology? Lessons from the United States (2019) (5)
2018 Selective bladder preservation by combined modality therapy for invasive bladder cancer (1995) (5)
Developing a National Radiation Oncology Registry (NROR): A Radiation Oncology Institute (ROI) Initiative (2011) (5)
Selective bladder preservation by combined modality treatment of invasive bladder cancer: 10-Year outcome (2001) (5)
Mapping Patterns of Nodal Metastases in Seminoma: Rethinking the Para-aortic Field (2011) (5)
Bone marrow suppression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement. (1997) (5)
Long-term Multi-institutional Analysis of Stage T1–T2 Prostate Cancer Treated with Permanent Brachytherapy (2005) (4)
Radiation Therapy in a Time of Disaster. (2018) (4)
Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy. (2011) (4)
1129: The Post-Treatment PSA Bounce for Prostate Cancer Patients Treated With External Beam RT or Permanent Brachytherapy Alone Is Not Biochemically or Clinically Significant: A Multi-Institutional Pooled Analysis of More Than 7500 Patients (2006) (4)
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 (2022) (4)
Imagining Our Lives Post-Pandemic (2020) (4)
Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-preserving approach (2008) (4)
Carcinoma of the Upper Urinary Tract (2017) (4)
Long-term outcome for men with prostate cancer treated with radiation as solo therapy (1994) (4)
Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. (2011) (4)
The Red Journal's Top Downloads of 2014. (2015) (4)
Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. (2013) (4)
The American Board of Radiology radiation oncology Maintenance of Certification Part 3 Modular Examination: Evaluation of the first administration. (2016) (3)
A three-dimensional ct based analysis of inter-fraction bladder motion during radiotherapeutic treatment of bladder cancer (2004) (3)
Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233. (2014) (3)
Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy. (2002) (3)
The Red Journal's Top Downloads of 2015. (2016) (3)
Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. (2001) (3)
Frailty is our Destiny: An Introduction to the Red Journal's Special Edition on Radiation Therapy in the Elderly. (2017) (3)
Complications of prostate cancer treatment. (2014) (3)
Hormonal therapies: ADT for prostate cancer: true love or heartbreak? (2010) (3)
The case for radiotherapy with or without chemotherapy in high-risk superficial and muscle-invading bladder cancer. (1997) (3)
Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: urodynamic and quality of life evaluation of patients treated by trimodality therapy (2002) (3)
A Phase III Trial Employing Conformal Photons with Proton Boost in Early-stage Prostate Cancer: Conventional Dose (70.2 GyE) Compared to High-dose Irradiation (79.2 GyE): Long-term Updated Analysis of Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95–09 (2009) (3)
The National Radiation Oncology Registry: Approaches to Regulatory Compliance to Promote Wide Participation (2013) (3)
Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer (2015) (3)
Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base. (2012) (3)
A (relatively) risky business: the link between prostatic radiotherapy and second malignancies (2016) (3)
Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. (2017) (3)
Radiation, chemotherapy and transurethral surgery: an organ-sparing alternative to the radical cystectomy. (2002) (3)
Transrectal ultrasound-guided prostate fiducial marker placement for prostate localization during external beam radiotherapy: a safe and reliable procedure (2013) (3)
Prostatectomy or watchful waiting in prostate cancer. (2003) (3)
141 Overall survival and local control following combined modality therapy and selective bladder preservation for invasive bladder cancer (1996) (3)
Clinical outcomes and prognostic factors in 4839 patients treated with external radiotherapy for stage T1-T2 prostate cancer (2004) (3)
Predicting outcome after PSA failure in prostate cancer patients treated by radiation. Who needs salvage therapy (2004) (3)
Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer. (2011) (3)
Definitions of biochemical control after permanent interstitial brachytherapy as sole treatment for localized prostate cancer: Interpreting the psa bounce (2004) (2)
Spermatic cord sarcoma: The role of adjuvant external beam irradiation (1994) (2)
Chapter 52 – Bladder Cancer (2012) (2)
2321: Treatment of Prostate Cancer With Photon IMRT and Proton Therapy: a Treatment Planning Comparison (2006) (2)
Dosimetric Validation of Robotic Prostate SBRT With Simultaneous Integrated Dose Escalation to Dominant Intraprostatic Lesion Using a Magnetic Resonance–Based 3D-Printed Prostate Model in an Anthropomorphic Pelvis Phantom (2016) (2)
Why Is Proton Beam Therapy So Controversial? (2015) (2)
ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist. (2020) (2)
Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial (2017) (2)
Quality of life assessment in women after combined modality treatment with bladder conservation for invasive bladder cancer (1994) (2)
An assessment of the in vitro radiosensitivity of a human prostate cancer cell line: The influence of the hormonal millieu (1994) (2)
Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder Cancer (2019) (2)
Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer. (2007) (2)
Restricted Access to Abortion, the Dobbs Ruling, and Radiation Oncology: Standing United Against Reproductive Injustice. (2022) (2)
Re: Consensus Guidelines for Reporting Prostate Cancer (2016) (2)
Can sex and seniority predict the quality of a journal reviewer's manuscript critique? (2021) (2)
Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer (2013) (2)
The growth and cell kinetics of a secondary tumor after radiation or surgical treatment of the primary tumor. (1987) (2)
Results from the Quality Research in Radiation Oncology (QRRO) Survey Evaluating Adherence to Quality Measures for Prostate Cancer Radiotherapy (2010) (2)
Editorial Statement on Gleason Scoring for Prostate Cancer. (2016) (2)
Making Sure Retractions Matter. (2019) (2)
Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (2)
1013 Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease (1995) (2)
Early salvage versus adjuvant post-prostatectomy radiation therapy: Long-term results of a large institutional experience. (2016) (2)
The Red Journal's outstanding reviewers of 2013. (2014) (2)
PSA failure free survival following irradiation for stage T1–T2 prostate cancer patients: The results of an ASTRO sponsored pooled analysis (1998) (2)
Case records of the Massachusetts General Hospital. Case 9-2012. A 67-year-old man with a persistently elevated PSA level. (2012) (2)
Fifty years from Paris: the remarkable story of the lymphomas. (2015) (2)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy. (2004) (2)
203 Bladder cancer: The combination of chemotherapy and irradiation in the treatment of patients with muscle-invading tumors (1993) (2)
Conservative Management Outcomes of Localized Prostate Cancer Following (2009) (2)
Curing Metastatic Disease With Ablative Radiation Therapy: Separating Truth From Wish. (2020) (2)
Early stage testicular seminoma: the role of radiation therapy following orchiectomy. (1994) (2)
The Red Journal's Top Downloads of 2019. (2020) (2)
Outcomes and Tolerability of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer in Elderly Patients (2017) (2)
A cost-effectiveness analysis of surveillance, radiotherapy, and carboplatin in the management of stage I testicular seminoma. (2006) (2)
Clinical Needs Assessment for Sexual Health Among Cancer Patients Receiving Pelvic Radiation (2016) (2)
Prostatic Duct Adenocarcinoma: Clinical Characteristics, Treatment Options and Outcomes: A Rare Cancer Network Study (2009) (2)
Cancer-related morbidity at the end of life in men with prostate cancer. (2018) (1)
UROLOGIC ONCOLOGY: PROSTATE CANCER Failure Definition-Dependent Differences in Outcome Following Radiation for Localized Pros- tate Cancer: Can One Size Fit All? (2005) (1)
Using patient-reported outcomes for technology assessment (TA) and quality improvement (QI) in prostate cancer brachytherapy (2007) (1)
Views on Global Health Among Radiation Oncology Residency Program Directors: A Knowledge, Attitudes, and Practices Survey (2018) (1)
Case 9-2003 (2009) (1)
Impact of Rectal Bleeding on Quality of Life Measures After Prostate Radiation Therapy: Comparison of the EPIC-26 and EPIC-CP Instruments (2015) (1)
Multidisciplinary care and management of very low-risk prostate cancer. (2013) (1)
Endorectal Balloon in Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Prostate Cancer: A Planning and Dosimetry Analysis (2012) (1)
Feasibility of Hemi-prostate Dose Escalation to 91 Gy with 3D-conformal vs. Intensity-modulated Proton Therapy (2009) (1)
Combined modality therapy as a means of blandder preservation for invasive bladder cancer (1998) (1)
American Urological Association ( AUA ) Guideline EARLY DETECTION OF PROSTATE CANCER : AUA GUIDELINE (2018) (1)
Organ preservation approaches with radiation therapy in muscle-invasive bladder carcinoma. (1996) (1)
Prognostic risk group stratification for clinical and biochemical failure after external beam radiation of localized prostate cancer (2004) (1)
Salvage radiation therapy after radical prostatectomy for prostate adenocarcinoma: Analysis of biochemical control and prognostic factors (2000) (1)
Radiation Therapy and the Immune System: A Scientific Revolution in the Making. (2020) (1)
Case 9-2012 (2012) (1)
Impact of Post-Prostatectomy Prostate Specific Antigen (PSA) Kinetics on Outcomes of Salvage Radiotherapy (2019) (1)
Fifteen-year Outcomes of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer: The Long-term MGH Experience (2009) (1)
Quantitative Isotransplantation and Xenotransplantation of Rat Rhabdomyosarcoma Ba1112 (1987) (1)
Global Health Perspectives among Radiation Oncology Residency Program Directors: A Knowledge, Attitudes, and Practices Survey. (2020) (1)
In regard to Shah. (2013) (1)
Long-term Outcomes After Bladder Preserving Combined Modality Therapy for Muscle-invasive Bladder Cancer: A Pooled Analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233 (2012) (1)
External Validation of Early Quality of Life (QOL) Declines Correlated with Late QOL after Intensity Modulated, Low Dose Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer within a Prospective Trial (2020) (1)
Radiotherapy practice patterns for men with cancero of the prostate. The 1994 pattens of cafe study (1998) (1)
Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 (2020) (1)
Genitourinary cancer committee (2001) (1)
The Red Journal's Outstanding Reviewer Awards for 2014. (2015) (1)
Adjuvant Radiation Therapy for Early Stage Seminoma: A Proton-photon Treatment Planning Comparison (2010) (1)
Adjuvant radiation therapy for early-stage seminoma: Proton-photon comparison and second cancer risk. (2011) (1)
VEGF-D Expression Predicts Biochemical Outcome in Localized Prostate Cancer Treated with External Radiation: A Ten Year Cohort Analysis (2005) (1)
In Reply to Ms. Albertini et al. (2007) (1)
VEGF-D expression predicts biochemical outcome in localized prostate cancer treated with external radiation: A ten-year cohort analysis (2005) (1)
Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base. (2012) (1)
Can Gender Predict Differences in Behavior, Manuscript Ratings, and Quality of Reviews Among Red Journal Reviewers? (2016) (1)
The Growth and Cell-Kinetics of a Secondary Tumor After Radiation or Surgical-Treatment of the Primary Tumor (1989) (1)
Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial (2020) (1)
Re: Endocrine Treatment, with or without Radiotherapy, in Locally Advanced Prostate Cancer (SPCG-7/SFUO-3): An Open Randomised Phase III Trial (2009) (1)
Expression of Editorial Concern: Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:e457-e462. (2021) (1)
2124 TRANSPERINEAL TEMPLATE-GUIDED PROSTATE BIOPSY FOR PERSISTENTLY ELEVATED PSA FOLLOWING MULTIPLE NEGATIVE BIOPSIES (2011) (1)
Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy. (2017) (1)
MP26-12 INCIDENCE AND MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCES AFTER COMPLETE RESPONSE TO COMBINED-MODALITY ORGAN-PRESERVING THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER (2015) (1)
Utilization of Potentially Curative Therapies for Muscle Invasive Bladder Cancer: Results From the National Cancer Data Base (2012) (1)
Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series. (2022) (1)
The Red Journal's Outstanding Reviewer Awards for 2016. (2017) (1)
Multi-institutional Patient-reported Quality of Life After Proton Therapy for Prostate Cancer Compared to Nontreated Men (2012) (1)
Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease. (2021) (1)
American society for radiation oncology intersociety summit summary. (2010) (1)
Definitions of biochemical failure that best predict clinical failure in prostate cancer patients treated with external beam radiation alone- a multi-institutional pooled analysis (2003) (1)
The prognostic impact of a negative confirmatory biopsy in men on active surveillance for prostate cancer. (2018) (0)
A PHASE MI TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCER CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY (1998) (0)
Renal function in bladder cancer patients after trimodality therapy: Long-term results of a large institutional experience. (2016) (0)
The prognostic utility of hemoglobin and lymphocytopenia in bladder-sparing therapy. (2017) (0)
1004 The value of external beam radiation in pathologic node positive prostate cancer: A multivariate analysis (1997) (0)
Comparison of Imaging Dose From Daily Cone Beam CT to Out-of-Field Therapeutic Dose in IMRT and VMAT Treatments of Prostate Cancer (2012) (0)
Table 110-6, Overall 5-year Survival and Bladder Preservation: Modern Series (1997-1998) (2003) (0)
Words of wisdom. Re: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. (2009) (0)
Title Global Pattern of Nasopharyngeal Cancer : Correlation ofOutcome With Access to Radiation Therapy (2016) (0)
1821 GLEASON UPGRADING AND INCREASED CANCER VOLUME ON REPEAT PROSTATE BIOPSY IN PATIENTS ON ACTIVE SURVEILLANCE (2012) (0)
Red Journal Readers' Top Articles From 2017. (2018) (0)
Long-term Quality of Life After Definitive Treatment for Prostate Cancer: Patient Reported Outcomes in the Second Post-treatment Decade (2012) (0)
In reply to Drs. Rubin and Hansen (2006) (0)
Reply from Authors re: Giuseppe Simone, Michele Gallucci. Multimodality Treatment Versus Radical Cystectomy: Bladder Sparing at Cost of Life? Eur Urol 2012;61:712–3: Bladder-Sparing Therapy: The Urologist Doth Protest Too Much, Methinks (2012) (0)
Counseling the Patient With Prostate Cancer (2004) (0)
Prostate brachytherapy technique and long-term urinary incontinence: 5-year outcomes of a prospective comparative cohort study. (2014) (0)
685 OUTCOMES OF RADIOTHERAPY AMONG MEN WITH LOW-RISK LOCALIZED PROSTATE CANCER (2012) (0)
Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis. (2018) (0)
The Red Journal's Outstanding Reviewers of 2018. (2019) (0)
Concomitant Radiation and Chemotherapy in Muscle-Invasive Bladder Cancer (2006) (0)
CaP Calculator: An Online Decision Support Tool to Improve Evidence-based Doctor-Patient Communication for Clinically Localized Prostate Cancer (2008) (0)
Pretreatment PSA is a powerful independent predictor of outcome following treatment of prostate carcinoma by radical radiotherapy (1993) (0)
Anatomical Differences after Robotic-assisted Radical Prostatectomy (RARP) and Open Prostatectomy (O (2009) (0)
In reply to Bauman. (2014) (0)
Reply to Carl J. Rossi's Comment on "Proton beam and prostate cancer: An evolving debate" by Anthony Zietman [Rep. Pract. Oncol. Radiother. 2013;18:338-42]. (2013) (0)
Feasibility of Gene Expression Signature Analysis in Prostate Cancer Biopsy Specimens to Predict Outcomes Following Radiation Therapy (2013) (0)
Signs and Symptoms (2018) (0)
Long-term Results of Early Salvage Versus Adjuvant Postprostatectomy Radiation: A Large Institutional Experience (2015) (0)
Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy (2022) (0)
Physician Bias, Referral to a Medical Oncologist, and Active Surveillance in Low-risk Prostate Cancer (2012) (0)
Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields. (2012) (0)
Herman Suit, MD, DPhil: Inspirational Physician, Scholar, and Gentleman. (2023) (0)
Multimodality Management in Primary Urethral Cancer: The Role of Radiation Therapy (2013) (0)
459 The treatment of localized prostate cancer by external beam irradiation: Long-term freedom from biochemical recurrence (1995) (0)
Mixed Methods Evaluation of a Targeted One-Week Virtual Radiation Oncology Intensive Shadowing Experience for Medical Students Underrepresented in Medicine: Mentor's Perspective. (2021) (0)
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. (2012) (0)
Prospective Validation of Single Nucleotide Polymorphisms as Predictors of Rectal Toxicity Following Radiation Therapy for Prostate Cancer (2019) (0)
Androgen deprivation with radiotherapy: how long is long enough? (2015) (0)
1573: Semen Analysis in Men with Prostate Cancer Whose Partners Became Pregnant (2004) (0)
Intersociety Radiation Oncology Summit-SCOPE II. (2008) (0)
31 A comparison between neoadjuvant and adjuvant androgen withdrawal with radiation in an experimental rodent model (1996) (0)
Statement From the Editors. (2019) (0)
2232 : Pelvic Irradiation for Rectal Cancer Is Associated With a Decreased Risk of Subsequent Clinically Detected Prostate Cancer (2006) (0)
National Radiation Oncology Registry: The pilot prostate cancer registry. (2012) (0)
The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601 (2020) (0)
Is radiation therapy superior to conservative management in men with localized prostate cancer? (2011) (0)
Late GI and GU sequelae in the second decade following high dose conformal radiation to 77.4 Gy with combined photons/protons for T3-4 prostate cancer (2000) (0)
OC-0057: Randomized phase 2 trial of radiation with either gemcitabine or 5FU/cisplatin in bladder cancer (2018) (0)
Squamous Cell Carcinoma (2003) (0)
Early Quality of Life (QOL) Declines Correlate With Later QOL After Intensity Modulated Radiation Therapy, Low-Dose-Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer (2014) (0)
Qualitative and Quantitative Analysis of a Deep Learning Auto Contouring Model for Radiotherapy in Localized Prostate Cancer. (2021) (0)
Radioactive seeds for prostate cancer. (1998) (0)
The effect of prostate brachytherapy technique on quality of life outcomes: 5-year outcomes of a prospective cohort study. (2014) (0)
The "Lee Decade": Bringing PRO from Conception to Maturity. (2019) (0)
Adenocarcinoma of the Bladder (2003) (0)
Outcomes of conservatively managed localized prostate cancer. (2009) (0)
SU-E-T-616: Comparison of Plan Dose Accuracy for Anterior Vs. Lateral Fields in Proton Therapy of Prostate Cancer. (2014) (0)
Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients. (2017) (0)
Dosimetric Analysis of Radiation Treatment Plans Based on a Deep Learning Auto Contouring Model for Patients with Localized Prostate Cancer (2022) (0)
Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder. (2013) (0)
Outcomes With Full Dose Re-irradiation With Curative Intent for Secondary Anorectal Cancers Following Prostatic Radiation Therapy (2014) (0)
Interstitial implant alone with or without external beam radiation therapy for intermediate risk localized prostate cancer: Patterns of Care Study in the United States (2006) (0)
Widespread Use of Multiparametric MRI in an Active Surveillance Cohort Results in Earlier Identification and Treatment of Clinically Significant Prostate Cancer (2019) (0)
Multi-institutional Prospective Evaluation of Bowel Quality of Life after Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated with Patient Reported Outcomes (2011) (0)
Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade: A. Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr. J Urol 2016; 195: 1723 (2016) (0)
MP62-14 LONG-TERM RESULTS OF POST-PROSTATECTOMY RADIOTHERAPY: A LARGE INSTITUTIONAL EXPERIENCE (2015) (0)
The Red Journal's Outstanding Reviewers of 2019. (2020) (0)
Five year results following permanent prostate seed implantation in consecutive patients treated at two academic institutions (2002) (0)
Evaluation of a prostate brachytherapy technique designed to reduce short- and long-term urinary dysfunction: 5-year results of a multi-institutional comparative cohort study. (2011) (0)
Nomogram for Predicting Risk of Cystectomy or Recurrence after Bladder Preserving Trimodality Therapy for Muscle Invasive Bladder Cancer (2011) (0)
Whither Thou Goest, I Will Go. (2018) (0)
Think Carefully, Publish Safely: Co-Authorship and Conflict of Interest Verification in the ASTRO Journals. (2019) (0)
PSA Bounces After Neoadjuvant Androgen Deprivation and External Beam Radiation: Impact on Definitions of Failure (2006) (0)
141 Thymosin B15 staining predicts for distant failure in patients with prostate cancer who are clinically M0 at presentation (1999) (0)
Point and counterpoint. Radical cystectomy or multimodality therapy for TCC of the bladder? (1995) (0)
In reply to Lee. (2014) (0)
Body Mass Index and PSA Failure Following Brachytherapy for Localized Prostate Cancer (2007) (0)
Ten Years, Hundreds of Editors, and Thousands of Manuscripts: Closing My Account at the Red Journal. (2021) (0)
Radiation response of xenografts of human tumors in nude mice (1987) (0)
Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. (2016) (0)
Interfractional variations in the set-up of pelvic bony anatomy and soft tissue , and their implications on the delivery of proton therapy for localized prostate cancer (2011) (0)
Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience. (2016) (0)
Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. (1994) (0)
A Population-Based Treatment Margin for Respiratory Motion of Lung Tumors (2013) (0)
A prospective comparison of the effects of interfractional variations on proton therapy and IMRT for prostate cancer (2016) (0)
Do patients with low-risk and intermediate-risk prostate cancer benefit from androgen deprivation? (2005) (0)
Late Breaking Abstracts LBA 1 Two Years of AntiAndrogen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy : A Secondary Analysis of the NRG Oncology / RTOG 9601 Randomized Phase III Trial (2019) (0)
Prospective Evaluation of a Digital RNA Circulating Tumor Cell Signature in Localized Prostate Cancer (2018) (0)
SU-E-J-150: Impact of Intrafractional Prostate Motion On the Accuracy and Efficiency of Prostate SBRT Delivery: A Retrospective Analysis of Prostate Tracking Log Files. (2014) (0)
Impact of the COVID-19 Pandemic on Prostate Cancer Radiotherapy Practice Patterns: A Northeast Regional Longitudinal Survey Study (2021) (0)
The Red Journal's Top Downloads of 2016. (2018) (0)
SU‐E‐T‐457: Impact of Interfractional Variations On Anterior Vs. Lateral‐Field Proton Therapy of Prostate Cancer (2015) (0)
Prospective validation of single nucleotide polymorphisms as predictors of gastrointestinal, genitourinary, and sexual toxicities following radiation therapy for prostate cancer. (2023) (0)
PD55-08 WIDESPREAD USE OF MULTIPARAMETRIC MRI IN AN ACTIVE SURVEILLANCE COHORT RESULTS IN EARLIER IDENTIFICATION AND TREATMENT OF CLINICALLY SIGNIFICANT PROSTATE CANCER (2019) (0)
The impact of a positive family history on clinical and pathologic outcomes of active surveillance for prostate cancer. (2021) (0)
Practice-Based Evidence to Evidence-Based Practice: Initial Challenges in Building the NROR (2013) (0)
Chapter 54 – Bladder Cancer (2016) (0)
PD42-01 PROPENSITY MATCHED COMPARISON OF RADICAL CYSTECTOMY WITH TRIMODALITY THERAPY FOR MUSCLE INVASIVE BLADDER CANCER (MIBC): A MULTI-INSTITUTIONAL STUDY (2022) (0)
Long-term QOL Outcome after Proton Radiation for Localized Prostate Cancer (2010) (0)
Recent Trends of “Manels” and Gender Representation among Panelists at North American Annual Radiation Oncology Meetings (2022) (0)
Clinical Outcomes of Combined Modality Bladder-Sparing Therapy for Patients With Histologic Variants of Bladder Cancer (2016) (0)
MP56-14 LONG-TERM RENAL FUNCTION IN PATIENTS UNDERGOING TRIMODAL THERAPY FOR BLADDER CANCER (2023) (0)
Superficial Bladder Carcinoma (2020) (0)
Propensity matched comparison of radical cystectomy with trimodality therapy for muscle invasive bladder cancer (MIBC): A multi-institutional study (2022) (0)
Can Demographic Factors or Academic Metrics of Red Journal Reviewers Predict the Quality of their Reviews? (2018) (0)
PROTON THERAPY FOR PROSTATE CANCER (2013) (0)
Pediatric medulloblastoma: Is proton beam the only ethically appropriate radiation treatment? (2013) (0)
Bladder-Conserving Therapy for Invasive Bladder Cancer Using Transurethral Surgery, Chemotherapy, and Radiation Therapy with Patient Selection by Initial Treatment Response (1998) (0)
Chemotherapy for Metastatic Disease (2003) (0)
Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (0)
Radiation Therapy in the Management of Locally Advanced Prostate Cancer (2012) (0)
Long-term outcomes after bladder-preserving combined-modality therapy for patients with muscle-invasive bladder cancer. (2016) (0)
A pair of deep learning auto-contouring models for prostate cancer patients injected with a radio-transparent versus radiopaque hydrogel spacer. (2023) (0)
Longitudinal trends of "manels" and gender representation at the ASCO Genitourinary Cancers Symposium. (2022) (0)
Using patient-reported outcomes to assess prostate brachytherapy technique (2005) (0)
Quantitative and Qualitative Evaluation of a Deep Learning Auto Contouring Model for Prostate Cancer Patients With Hydrogel Spacer (2020) (0)
Simultaneous evaluation of determinants of radiocurability: Intrinsic cell radiosensitivity,, clonogenic fraction, and hypoxic fraction (1993) (0)
Factors Associated With Clinical-Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Implications for Treatment Selection and Comparative Studies (2012) (0)
MP48-19 NEED FOR INTERVENTION AND SURVIVAL IN A COHORT OF PATIENTS ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2019) (0)
Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial. (2018) (0)
Radiation Therapy for Stage IIA/B Seminoma: Modeling Secondary Cancer Risk for Protons and VMAT vs. 3D Photons (2022) (0)
SP-0220: Publishing the science of radiation oncology: the perspective of the Red Journal's editor (2016) (0)
Referral to a Multidisciplinary Genitourinary Oncology Clinic Increases Rates of Active Surveillance in Low-risk Prostate Cancer (2011) (0)
SU-FF-T-71: Effect of Daily Shifts of IMRT Prostate Patients On Dose to Pelvic Nodes (2005) (0)
Can proton therapy be considered a standard of care in oncology? Lessons from the United States (2019) (0)
1822 NEED FOR INTERVENTION AND SURVIVAL IN A COHORT OF PATIENTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER (2012) (0)
ACTIVE SURVEILLANCE FOR LOW‐RISK PROSTATE CANCER IN MEN UNDER 60 YEARS OF AGE: PD55‐03 (2017) (0)
Inverse probability treatment weighting comparison of radical cystectomy to trimodality therapy for cT2-cT4 muscle invasive bladder cancer (2023) (0)
TU‐EF‐304‐05: Anterior Proton Beams for Prostate Treatments Lead to Substantial Elevations in Modeled RBE‐Weighted Rectal Dose (2015) (0)
Association of Statin Use with Local Control in Patients Treated with Selective Bladder Preservation for Muscle-Invasive Bladder Cancer (2005) (0)
Long-term QOL outcome after proton beam monotherapy for localized prostate cancer. (2011) (0)
Oral Scientific SessionsMulti-institutional Outcomes of Postprostatectomy Adjuvant Versus Early Salvage Radiation Therapy in Prostate Cancer Patients With Adverse Pathologic Features (2017) (0)
PD09-03 INVERSE PROBABILITY TREATMENT WEIGHTING COMPARISON OF RADICAL CYSTECTOMY TO TRIMODALITY THERAPY FOR CT2-CT4 MUSCLE INVASIVE BLADDER CANCER (2023) (0)
2053 Probability of subsequent failure in men with prostate cancer clinically disease free 10 years after treatment with radiation therapy (1996) (0)
RISE: An Equity and Inclusion-based Virtual Pipeline Program for Medical Students Underrepresented in Medicine (2021) (0)
In Reply to Royce et al. (2021) (0)
PD17-05 THE IMPACT OF A POSITIVE FAMILY HISTORY OF HEREDITARY CANCER-ASSOCIATED MALIGNANCIES ON OUTCOMES OF ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2021) (0)
The Natural History of Nonmuscle-Invasive Bladder Cancer Recurrences After Complete Response to Combined-Modality Organ-Preserving Therapy for Muscle-Invasive Bladder Cancer (2016) (0)
The Red Journal's Top Downloaded Articles in 2020. (2021) (0)
The Red Journal's Top Reviewers from 2020. (2021) (0)
Robustness of Proton Therapy Versus IMRT to Interfractional Variations for Prostate Cancer Treatments (2014) (0)
SU-G-JeP4-09: Impact of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy for Prostate Cancer. (2016) (0)
Correlating Patient Reported Symptoms after High Dose Proton Irradiation for Localized Prostate Cancer with Dose Volume Histogram Parameters (2009) (0)
101 : Long-term Multi-Institutional Outcome and biochemical Failure Definition Analysis of Combined Permanent Brachytherapy With External Beam Radiation for Prostate Cancer (2006) (0)
Neoadjuvant androgen suppression and external beam radiation therapy. (2002) (0)
Retraction Notice (2016) (0)
Defining Biochemical Control After Prostate Brachytherapy: Can We Use a Target PSA? (2005) (0)
The Red Journal's Top Downloads of 2018. (2019) (0)
Abstract of Astro scientific papers to be presentedThe transplantability of human tumors into control and immune modified nude mice (1987) (0)
Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. (2013) (0)
MP49-17 CLINICAL OUTCOMES OF PATIENTS WITH HISTOLOGIC VARIANTS OF BLADDER CANCER TREATED WITH TRIMODAL BLADDER-SPARING THERAPY (2016) (0)
Cell kinetic factors predicting local control following radiation therapy for prostate cancancer: An assessment of % s-phase, total proliferative fraction and DNA ploidy (1993) (0)
Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer. (2011) (0)
Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-Term Results of a Large Institutional Experience (2016) (0)
Complications of Prostate Brachytherapy: Cause, Prevention, and Treatment (2007) (0)
Hypofractionated Versus Conventionally Fractionated Radiation Therapy for Prostate Cancer: Five-Year Oncologic Outcomes of the Dutch Randomized Phase 3 HYPRO Trial (2015) (0)
In Reply to Tokuuye. (2017) (0)
Comparative Effectiveness Analysis of Patient-Reported Quality of Life (QOL) After Stereotactic Body Radiation Therapy as Compared to Intensity Modulated Radiation Therapy or Low-Dose-Rate Brachytherapy up to 2 Years After Treatment (2014) (0)
Jim Cox-The Passing of an Era. (2019) (0)
MP17-14 THE PROGNOSTIC IMPACT OF A NEGATIVE CONFIRMATORY BIOPSY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2018) (0)
Prostatectomy vs radiation therapy for prostate cancer: The (still) unsolved dilemma. (2016) (0)
Higher suspicion with a lower PSA: Skeletal metastases after radical radiation therapy for localized prostate cancer (1998) (0)
Radiation treatment in prostate cancer: covering the waterfront (2021) (0)
Hydrogel rectum-prostate spacers and anterior-oblique proton beams ” (2017) (0)
In reply to Raju. (2014) (0)
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer. (2023) (0)
Does prostate brachytherapy that avoids the central zone prevent long-term urinary incontinence? Five-year results of a multi-institutional comparative cohort study. (2011) (0)
ACTIVE SURVEILLANCE IS A VIABLE OPTION FOR MEN WITH BORDERLINE LOW‐RISK PROSTATE CANCER: PD55‐05 (2017) (0)
Radiation Therapy for Clinically Localized Prostate Cancer (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Anthony Laurence Zietman?

Anthony Laurence Zietman is affiliated with the following schools:

Massachusetts General Hospital